The Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research funding opportunity, issued by the National Cancer Institute (NCI) under the National Institutes of Health (NIH), supports currently funded U01 research projects seeking to integrate innovative technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program. The goal is to enhance the original research aims, accelerate scientific progress, and validate emerging tools and methods for broader adoption by the cancer research community. These technologies are expected to address critical gaps in current methodologies and contribute to cancer prevention, detection, diagnosis, and treatment advancements. Proposals must demonstrate how the incorporation of IMAT-supported technologies will offer a clear advantage over existing tools and accelerate progress in the parent study.

The IMAT program focuses on the development, integration, and dissemination of highly innovative molecular, cellular, and biospecimen analysis technologies to support cancer research and clinical care. Projects funded under this opportunity must propose meaningful collaborations, detailing how the IMAT-supported technology will independently validate findings, improve research rigor, and contribute to the broader scientific community. Applications should also highlight how these technologies address limitations of existing approaches and enable new capabilities within cancer research.

Eligible applicants include public and private higher education institutions, nonprofits, small businesses, for-profit organizations, state and local governments, tribal organizations, and foreign institutions. Applications must be linked to an active NCI-funded U01 award with at least one year of funding remaining at the time of the proposed revision's start date. Projects cannot request funding beyond the parent award's end date, and funds cannot be used during a no-cost extension period. Individual investigators from diverse backgrounds are encouraged to apply, and all applicants must meet NIH registration and compliance requirements, including active registrations in SAM.gov, eRA Commons, and Grants.gov.

The budget for revision applications is capped at $150,000 per year in direct costs, with a maximum project period of two years. The parent U01 principal investigator must be included in the application, and proposals should introduce at least one new specific aim directly tied to the incorporation of the IMAT-supported technology. Applications must include a clear research strategy, detailing how the proposed technology will address existing challenges, enhance the parent study, and validate the technology’s broader relevance to cancer research. Applicants are also required to provide a resource-sharing plan and comply with NIH data management and sharing policies.

Proposals will be evaluated based on three main criteria: the importance of the research (significance and innovation), rigor and feasibility of the approach, and the expertise and resources available to execute the project successfully. Additional factors include protections for human subjects, plans for inclusion of diverse populations, biohazard safety measures, and budget justification. Applications will undergo peer review, and funding decisions will consider scientific merit, alignment with NCI priorities, and availability of funds.

Letters of intent are encouraged but not required and must be submitted at least 30 days before the application due date. Application deadlines are set for April 4, 2025, and October 3, 2025. Successful applicants will receive a Notice of Award (NoA) and must comply with all NIH reporting and regulatory requirements. For additional guidance, applicants are encouraged to contact designated NCI program staff and review resources provided in the funding opportunity announcement.